Integrin α5β1 promotes survival of growth-arrested breast cancer cells: An in vitro paradigm for breast cancer dormancy in bone marrow

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4514-4522

  Korah, Reju ^a   Boots, Monika ^a   Wieder, Robert ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBRONECTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VERY LATE ACTIVATION ANTIGEN 5; AKT1 PROTEIN, HUMAN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; BONE MARROW; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; GENE CONTROL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROENVIRONMENT; MODEL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION; BONE MARROW CELL; BREAST TUMOR; CELL DIVISION; COCULTURE; PATHOLOGY; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BONE MARROW CELLS; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL SURVIVAL; COCULTURE TECHNIQUES; COLLAGEN TYPE I; COLLAGEN TYPE IV; FIBRONECTINS; HUMANS; INTEGRIN ALPHA5BETA1; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 3042819503     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3853     Document Type: Article

References (35)

1. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. New Engl J Med 2000;342: 525-33.
2. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocrine-Related Cancer 1999;6:333-47.
3. Braun S, Kentenich C, Janni W, et al. Lack of an effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J Clin Oncol 2000;18:80-6.
4. Ploemacher RE. Stem cells: characterization and measurement. Bailliere's Clin Haematol 1997;10:429-44.
5. Knaan-Shanzer S, Verlinden SF, van Beusechem VW, Van Bekkum DW, Valerio D. Intrinsic potential of phenotypically defined human hemopoietic stem cells to self-renew in short-term in vitro cultures. Exp Hematol 1999;27:1440-50.
6. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-63.
7. Sinowatz F, Schams D, Plath A, Kolle S. Expression and localization of growth factors during mammary gland development. In Mol JA, Clegy RA, editors. Biology of the mammary gland. New York: Kluwer Academic Press; 2000. p. 19-25.
8. McLeskey SW, Ding IYF, Lipman ME, Kern FG. MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res 1994;54:523-30.
9. Fenig E, Wieder R, Paglin S, et al. Basic fibroblast growth factor confers growth inhibition and MAP kinase activation in human breast cancer cells. Clin Cancer Res 1997;3:135-42.
10. 1 events. Cancer Res 1997;57:1750-7.
11. Johnson MR, Valentine C, Basilico C, Mansukhani A. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells. Oncogene 1998;16:2647-56.
12. Wang Q, Maloof P, Wang H, et al. Basic fibroblast growth factor (bFGF) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Exp Cell Res 1988;238:177-87.
13. Korah R, Sysounthone V, Golowa Y, Wieder R. Basic fibroblast growth factor confers a more differentiated phenotype in MDA-MB-231 human breast cancer cells. Cancer Res 2000;60:733-40.
14. Korah R, Sysounthone V, Scheff E, Wieder R. Intracellular FGF-2 promotes differentiation in T47-D breast cancer cells. Biochem Biophys Res Commun 2000;277:255-60.
15. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 2001;12:863-79.
16. Brunner G, Gabrilove J, Rifkin DB, Wilson EL. Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 1991;114:1275-83.
17. Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 1993;81: 631-8.
18. Gabrilove JL, White K, Rahman Z, Wilson EL. Stem cell factor and basic fibroblast growth factor are synergistic in augmenting committed myeloid progenitor cell growth. Blood 1993;83:907-10.
19. Brunner G, Metz CN, Nguyen H, et al. An endogenous glycosylphosphatidylinositol-specific phospholipase D releases basic fibroblast growth factor-heparan sulfate proteoglycan complexes from human bone marrow cultures. Blood 1994;83:2115-25.
20. Yoon SY, Li CY, Lloyd RV, Tefferi A. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodisplastic syndrome with myelofibrosis and related disorders. Int J Hematol 2000;72:337-42.
21. Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 1993;4:973-82.
22. Klein S, Bikfalvi A, Birkenmeier TM, Giancotti FP, Rifkin DB. Integrin regulation by endogenous expression of 18-kDa fibroblast growth factor-2. J Biol Chem 1996;271: 22583-90.
23. Orr FW, Lee J, Duivenvoorden WCM, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer 2000;88(Suppl 12):2912-8.
24. Matter ML, Ruoslahti E. A signaling pathway from the α5β1 and αvβ3 integrins that elevates bcl-2 transcription. J Biol Chem 2001;276:27757-63.
25. Lee JW, Juliano RL. α5β1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway. Mol Biol Cell 2000;11:1973-87.
26. Oliver LJ, Rifkin DB, Gabrilove JL, Hannocks M-J, Wilson EL. Long-term culture of human bone marrow stromal cells in the presence of basic fibroblast growth factor. Growth Factors 1990;3:231-6.
27. Wieder R, Fenig E, Wang H, et al. Overexpression of basic fibroblast growth factor in MCF-7 human breast cancer cells: lack of correlation between inhibition of cell growth and MAP kinase activation. J Cell Physiol 1998;177:411-25.
28. Luqmani YA, Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 1992;66:273-80.
29. Anandappa SY, Winstanley JHR, Leinster S, Green B, Rudland PS, Barraclough R. Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 1994;69:772-6.
30. Gomm JJ, Smith J, Ryall GK, Baille R, Turnbull L, Coombes RC. Localization of basic fibroblast growth factor and transforming growth factor β1 in the human mammary gland. Cancer Res 1991;51:4685-92.
31. Fenig E, Kanfi Y, Wang Q, et al. Role of transforming growth factor β in the growth inhibition of human breast cancer cells by basic fibroblast growth factor. Breast Cancer Res Treat 2001;70:27-37.
32. Kerkhoff E, Leberfinger CB, Schmidt G, Aktories K, Rapp UR. Diverse effects of RacV12 on cell transformation versus deregulation of cell cycle control. Biochim Biophys Acta 2002;1589:151-9.
33. Wang XQ, Sun P, Paller AS. Inhibition of integrin-linked kinase/protein kinase B/Akt signaling: mechanism for ganglioside-induced apoptosis. J Biol Chem 2001;276: 44504-11.
34. Feng Y, Wang LY, Cai T, et al. All-trans-retinoic acid increased the expression of integrin α5β1 and induced "anoikis" in SMMC-7721 hepatocarcinoma cell. J Exp Clin Cancer Res 2001;20:429-38.
35. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001;20:4995-5004.